These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 20511180)
1. ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Ammoun S; Cunliffe CH; Allen JC; Chiriboga L; Giancotti FG; Zagzag D; Hanemann CO; Karajannis MA Neuro Oncol; 2010 Aug; 12(8):834-43. PubMed ID: 20511180 [TBL] [Abstract][Full Text] [Related]
2. Treatment of vestibular schwannoma cells with ErbB inhibitors. Bush ML; Burns SS; Oblinger J; Davletova S; Chang LS; Welling DB; Jacob A Otol Neurotol; 2012 Feb; 33(2):244-57. PubMed ID: 22222570 [TBL] [Abstract][Full Text] [Related]
3. ErbB expression, activation, and inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas. Ahmad ZK; Brown CM; Cueva RA; Ryan AF; Doherty JK Otol Neurotol; 2011 Jul; 32(5):841-7. PubMed ID: 21659924 [TBL] [Abstract][Full Text] [Related]
4. Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib. Singh A; Lun X; Jayanthan A; Obaid H; Ruan Y; Strother D; Chi SN; Smith A; Forsyth P; Narendran A Mol Oncol; 2013 Jun; 7(3):497-512. PubMed ID: 23375777 [TBL] [Abstract][Full Text] [Related]
5. ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy. Doherty JK; Ongkeko W; Crawley B; Andalibi A; Ryan AF Otol Neurotol; 2008 Jan; 29(1):50-7. PubMed ID: 18199957 [TBL] [Abstract][Full Text] [Related]
6. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. Diaz R; Nguewa PA; Parrondo R; Perez-Stable C; Manrique I; Redrado M; Catena R; Collantes M; Peñuelas I; Díaz-González JA; Calvo A BMC Cancer; 2010 May; 10():188. PubMed ID: 20459769 [TBL] [Abstract][Full Text] [Related]
7. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy. Zhang Z; Oyesanya RA; Campbell DJ; Almenara JA; Dewitt JL; Sirica AE Hepatology; 2010 Sep; 52(3):975-86. PubMed ID: 20607690 [TBL] [Abstract][Full Text] [Related]
8. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2. Karakashev SV; Reginato MJ Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742 [TBL] [Abstract][Full Text] [Related]
9. Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma. Agnihotri S; Gugel I; Remke M; Bornemann A; Pantazis G; Mack SC; Shih D; Singh SK; Sabha N; Taylor MD; Tatagiba M; Zadeh G; Krischek B J Neurosurg; 2014 Dec; 121(6):1434-45. PubMed ID: 25245477 [TBL] [Abstract][Full Text] [Related]
10. Epidermal Growth Factor Receptor activation promotes ADA3 acetylation through the AKT-p300 pathway. Srivastava S; Mohibi S; Mirza S; Band H; Band V Cell Cycle; 2017 Aug; 16(16):1515-1525. PubMed ID: 28759294 [TBL] [Abstract][Full Text] [Related]
11. Allosteric modulation by protein kinase Cε leads to modified responses of EGF receptor towards tyrosine kinase inhibitors. Weisheit S; Liebmann C Cell Signal; 2012 Feb; 24(2):422-434. PubMed ID: 21964064 [TBL] [Abstract][Full Text] [Related]
12. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Xia W; Mullin RJ; Keith BR; Liu LH; Ma H; Rusnak DW; Owens G; Alligood KJ; Spector NL Oncogene; 2002 Sep; 21(41):6255-63. PubMed ID: 12214266 [TBL] [Abstract][Full Text] [Related]
13. ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor. Juliachs M; Castillo-Ávila W; Vidal A; Piulats JM; Garcia Del Muro X; Condom E; Hernández-Losa J; Teixidó C; Pandiella A; Graupera M; Casanovas O; Germà JR; Villanueva A; Viñals F Int J Cancer; 2013 Jul; 133(1):235-46. PubMed ID: 23292912 [TBL] [Abstract][Full Text] [Related]
14. Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells. Liu L; Shi H; Liu Y; Anderson A; Peterson J; Greger J; Martin AM; Gilmer TM Mol Cancer Ther; 2011 Mar; 10(3):518-30. PubMed ID: 21252284 [TBL] [Abstract][Full Text] [Related]
15. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Zhang D; Pal A; Bornmann WG; Yamasaki F; Esteva FJ; Hortobagyi GN; Bartholomeusz C; Ueno NT Mol Cancer Ther; 2008 Jul; 7(7):1846-50. PubMed ID: 18644997 [TBL] [Abstract][Full Text] [Related]
16. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression. Nencioni A; Cea M; Garuti A; Passalacqua M; Raffaghello L; Soncini D; Moran E; Zoppoli G; Pistoia V; Patrone F; Ballestrero A PLoS One; 2010 Feb; 5(2):e9024. PubMed ID: 20126311 [TBL] [Abstract][Full Text] [Related]
17. Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Imami K; Sugiyama N; Imamura H; Wakabayashi M; Tomita M; Taniguchi M; Ueno T; Toi M; Ishihama Y Mol Cell Proteomics; 2012 Dec; 11(12):1741-57. PubMed ID: 22964224 [TBL] [Abstract][Full Text] [Related]
18. A dual tyrosine kinase inhibitor lapatinib suppresses overexpression of matrix metallopeptidase 1 (MMP1) in endometrial cancer. Lin CY; Chao A; Wang TH; Hsueh S; Lee YS; Wu TI; Chao AS; Huang HJ; Chou HH; Chang TC; Lai CH J Mol Med (Berl); 2014 Sep; 92(9):969-81. PubMed ID: 24820961 [TBL] [Abstract][Full Text] [Related]
19. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A Neuro Oncol; 2011 Sep; 13(9):983-99. PubMed ID: 21778190 [TBL] [Abstract][Full Text] [Related]
20. The natural compound fucoidan from New Zealand Undaria pinnatifida synergizes with the ERBB inhibitor lapatinib enhancing melanoma growth inhibition. Thakur V; Lu J; Roscilli G; Aurisicchio L; Cappelletti M; Pavoni E; White WL; Bedogni B Oncotarget; 2017 Mar; 8(11):17887-17896. PubMed ID: 28060735 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]